Appointment of Director of Regulatory affairs

By in

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa appoints Dr Nick Horniman as its Director of Regulatory Affairs 

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle,has appointed, with immediate effect, Dr Nick Horniman, BVSc MRCVS, as its Director of Regulatory Affairs, a senior management role, tocoordinate the Company’s overall regulatory strategy and ongoing relationships with regulators. 

As Director of Regulatory Affairs, Nick will implement the Company’s licencing strategy through its continuing relationships with the relevant UK agencies and research centres surrounding the complex regulation of the cultivation of Cannabis.  This includes the Company’s engagement in research and export opportunities, growing licences for the cultivation of Cannabis for supply to pharmaceutical manufactures of Schedule 2 Cannabis Based Products for Medicinal use in Humans (“CBPMs”), and working with the Veterinary Medicines Directorate to explore the use of cannabis-based products for parallel treatment of animals, in particular the dog & cat pet market and the equine industry.  Agencies with which the Company is already in dialogue include the Medicines and Healthcare products Regulatory Agency (“MHRA”), the Food Standards Agency (“FSA”), The National Institute for Health and Care Excellence (“NICE”) and the Home Office Drugs Licensing and Compliance Unit.

Dr Horniman has thirty years’ experience in the veterinary industry, and, for more than 20 of those years, he set up and ran a group of private veterinary practices, which he has since sold.  In addition to this, he worked with corporate practices as a veterinary surgeon and consultant and has worked with online veterinary pharmacies and prescription software companies. Nick started out his veterinary career by completing his Bachelor of Sciences in Veterinary Science at the University of Bristol.  Nick is also the monthly veterinary surgeon on BBC Radio Gloucestershire. 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “CBD and medicinal cannabis are new industries in the UK and they are flourishing quickly to meet unmet demand from both patients of the medical profession and the wider medicinal cannabis and CBD markets, so the regulatory framework is being developed to mirror this.  Dr Horniman is liaising with the relevant agencies and research hubs for Sativa’s medicinal cannabis Growing Licence application, along with working with the FSA surrounding the regulation of CBD.  This helps Sativa implement its seed-to-consumer model and positions Sativa as having first mover advantage in the UK industry. 

“As announced in our Strategic and Trading Update, Sativa is also planning to enter the potentially lucrative CBD veterinary market through Sativa Veterinary services.  The CBD veterinary market has already taken off in North America and Dr Horniman will also advise on how best to go about launching the veterinary arm in the UK.”

Dr Horniman has been granted options over 3,076,923 ordinary shares in the Company with an exercise price of 6.5p per share. 

The Directors of the Company accept responsibility for the contents of this announcement. 

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard 


+44 (0) 20 7469 4633 / 4634



+44 (0) 20 7469 4630

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canadian-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.



Details of the person discharging managerial responsibilities / person closely associated



Nicholas Horniman


Reason for the notification



Director of Regulatory Affairs (Senior Management Position), Sativa Investments PLC



Initial notification /Amendment

Initial notification



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



 Sativa Investments PLC






Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each


ISIN: GB00BFX17474


Nature of the transaction

Grant of options


Price(s) and volume(s)


3,076,923 at an exercise price of 6.5p (£0.065), equal to £200,000


Aggregated information

– Aggregated volume

– Price



Date of the transaction

8th February 2019


Place of the transaction

NEX Exchange Growth Market

(0 votes. Average 0 of 5)
Leave a reply

Your email address will not be published. Required fields are marked *